Hemorrhagic Stroke
Conditions
Keywords
acute hemorrhagic stroke, Shengdi Dahuang Decoction
Brief summary
The purpose of this study is to assess the efficacy and safety of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke by the randomized, controlled, double-blind, multi-center trial design project.
Detailed description
The main purpose of the study is to observe the clinical efficacy and safety of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke. This project is funded by Science and Technology Commission of Shanghai Municipality and will be carried out in 5 hospitals. Investigators will recruit 464 participants who meet the inclusion criteria and agree to participate in the research. Participants will be randomly assigned into experimental or placebo group. Granules of Shengdi Decoction is the therapeutic drug used in the experimental group. Each pack of the test drug contains 15 grams of rehmannia and 5 grams of rhubarb. While for the placebo group, each pack contains 2% rehmannia and rhubarb. Participants will receive a follow-up observation in the following 90 days. Modified Rankin Scale score (mRS), the mortality rate on day 7 and day 90 after treatment, National Institute of Health Stroke Scale (NIHSS), expansion rate of hematoma, the degree of edema and the expressions of inflammatory indicators will be detected to evaluate the clinical efficacy of Shengdi Dahuang Decoction.
Interventions
DRUGGranules of Shengdi Dahuang Decoction
Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
DRUGPlacebo
Placebo granules has the same appearence, weight, shape and color as the experimental drug.
Sponsors
ShuGuang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Meet the diagnostic criteria of acute intracerebral hemorrhage； 2. CT scan reveals cerebral parenchymal hemorrhage and the volume of hematoma is \<80ml; 3. The time from onset to confirmed diagnosis by CT scan is within 4 hours; 4. Enrolled and receive treatment within 12 hours from onset; 5. Age ≥18 years old; 6. Obtain approval from the patient or family members.
Exclusion criteria
1. The time from onset to confirmed diagnosis by CT scan is over 4 hours; 2. CT scan indicate that the sites of hemorrhage are in the cerebellum, brainstem and ventricle (note: in case of cerebral parenchymal hemorrhage combined with ventricular hemorrhage, patients will be excluded if the volume of ventricular hemorrhage is the larger one); 3. The volume of hematoma is above 80ml; 4. Glasgow Coma Scale (GCS) is ≤ 5 points; 5. The time from onset to confirmed diagnosis is over 12 hours; 6. Have a surgical treatment planning within 24 hours; 7. Cerebral hemorrhage caused by trauma, arteriovenous malformation, thrombolytic therapy, anticoagulant therapy or other reasons; 8. Patients with disabilities before onset (modified mRS score \> 2); 9. Patients with severe primary diseases of the heart, lung, liver, kidney, endocrine systems or hematopoietic system; 10. Patients who have participated in other clinical trials within the past 1 month; 11. Pregnant or nursing women; 12. Allergic constitution (allergic to more than two kinds of food or medications).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disability rate | 90 days | Modified Rankin Scale score (mRS) will be graded on the 90th day after onset (mRS score ranges from 0 point (no symptoms at all) to 5 points (severe disability)). |
| Mortality rate on the 7th day | 7 days | The proportion of deaths (mortality rate, %) in different groups on 7th day after treatment will be compared. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rate on the 90th day | 90 days | The proportion of deaths (mortality rate, %) in different groups on 90th day after treatment will be compared. |
| Severity of neurological deficit | 7 days | National Institute of Health Stroke Scale (NIHSS) will be used to assess the severity of neurological deficit on the 7th day after treatment. NIHSS score ranges from 0 point to 42 points. More severe neurological deficit could be observed in participants with the higher score. |
| The proportion of hematoma enlargement cases | 24 hours | All participants will reexamine the skull CT scan 24 hours after onset. The volume of hematoma (ml) increases more than 6ml or 33% relative increment than original volume is defined as the expansion of hematoma. The proportion of hematoma enlargement cases (%) will be compared between different groups. |
| Severity of edema | 7 days | All participants will reexamine the skull CT scan on the 7th day after treatment. The volume (ml) of edema and hematoma will be calculated respectively. The ratio of edema volume and hematoma volume represents the severity of edema. |
Countries
China
Contacts
Primary ContactXiaoyu Yu
Outcome results
None listed